on 12-03-201307:18 AM - edited on 10-15-202109:28 AM by Closed Account
Stojko J, Debaene F, Xuan Y, Bromirski M, Van Dorsselaer A, Beck A, Cianférani S. 9th European Antibody Congress Poster With more than 30 candidates clinically approved since 1985, monoclonal antibodies (mAbs) have become the fastest growing class of biotherapeutic agents.
High target specificity as effector functions of these immunoglobulins, recently potentialized by drug conjugation, remain tightly bound to their structural features.
This source of heterogeneity, stemming from both mAbs production (encoding sequences, posttranslational modifications) and processing (engineered alterations, storage, administration) is now further enhanced by biosimilars arrival, involving a thorough characterization of these mosaic mixtures.
In this context, native ESI-MS combined to high resolution appears as a challenging approach to depict an exhaustive snapshot of in-solution species while preserving non covalent complexes. Brought together, these informations allow to concomitantly evidence mAbs heterogeneity and specificity.